Lotus Pharmaceutical Co Ltd

PTT Public Company Limited is considering strategic options for Lotus Pharmaceutical Co., a pharmaceutical company listed on the Taiwan stock exchange. One of the approaches under consideration is bringing in partners to support business expansion in the Asia-Pacific region, according to a Bloomberg report on September 4, 2026, citing sources familiar with the matter. The process is still in its early stages, with PTT working with advisors and having begun exploring interest from potential investors in Lotus Pharmaceutical. The sources, who requested anonymity, said PTT is seeking strategic partners that can help support Lotus Pharmaceutical's growth in Thailand and neighboring countries, which are key markets for the company. If the consideration proceeds, it could lead to a full acquisition of Lotus Pharmaceutical in a later phase, but no conclusions have been reached regarding the form or structure of any transaction.

Alvotech's stock climbed 11.7% after the company announced an expanded licensing and commercialization agreement with Lotus Pharmaceutical for biosimilar candidates AVT34 (Imfinzi) and AVT87 (Hemlibra) across the United States and eight Asian markets, with potential consideration of up to approximately US$150 million plus ongoing supply revenues. This deal, announced in August 2026, broadens Alvotech's access to oncology and hematology markets while keeping it in control of development, regulatory approvals, and global product supply. The expansion could modestly support near-term milestones, but the key short-term catalyst remains timely FDA and EMA decisions on late-stage assets. Alvotech's 2026 revenue guidance of US$650 million to US$700 million already relies heavily on product and milestone flows, so any payments from Lotus would sit inside that ambitious framework. The company's recent swing back to a net loss in the first half of 2026 underscores its dependence on approval timing and partner ramp-up.

Alvotech announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical covering two biosimilar candidates in the United States and selected Asian markets. The deal covers AVT34, a proposed biosimilar to Imfinzi, and AVT87, a proposed biosimilar to Hemlibra. Under a semi-exclusive U.S. agreement, Alvotech retains the right to commercialize both products directly alongside Lotus, while Lotus will commercialize through its U.S. subsidiary Alvogen. In Asia, Lotus gets exclusive rights in eight markets: South Korea, Taiwan, Thailand, Vietnam, the Philippines, Singapore, Hong Kong and Malaysia. The agreement has a potential value to Alvotech of up to approximately $150 million in upfront and milestone payments, plus ongoing supply revenues.